Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Has Average Target Price of $41.50

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $41.50.

AGIO has been the subject of a number of recent analyst reports. HC Wainwright increased their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. Royal Bank Of Canada lifted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Truist Financial decreased their price target on Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. Finally, Bank of America raised their price target on Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a report on Monday, September 21st.

Agios Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ:AGIO opened at $31.32 on Friday. The firm’s 50 day moving average is $33.08 and its two-hundred day moving average is $32.69. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The firm has a market capitalization of $1.87 billion, a P/E ratio of -4.47 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. Analysts predict that Agios Pharmaceuticals will post -5.83 EPS for the current year.

Insiders Place Their Bets

In related news, insider Sarah Gheuens sold 30,000 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the sale, the insider owned 54,645 shares of the company’s stock, valued at $1,665,579.60. This represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Nykredit A S bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $26,000. Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $43,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $47,000. Allworth Financial LP acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $73,000. Finally, Versant Capital Management Inc boosted its holdings in shares of Agios Pharmaceuticals by 378.7% in the second quarter. Versant Capital Management Inc now owns 2,001 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 1,583 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases. Based in Cambridge, Massachusetts, the company specializes in cellular metabolism and the development of therapies designed to address underlying disease biology rather than only treating symptoms.

Agios’ lead commercial product is Pyrukynd (mitapivat), an oral pyruvate kinase activator approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.